Title:
SMALL MOLECULE GLP-1 RECEPTOR MODULATOR
Document Type and Number:
WIPO Patent Application WO/2021/018023
Kind Code:
A1
Abstract:
The present invention provides a new compound for modulating a Glucagon-like peptide-1 (GLP-1) receptor, and a synthesis method therefor and a pharmaceutical use thereof. This kind of compound has an obvious agonistic effect on the GLP-1 receptor, but does not have an obvious binding effect on hERG, and therefore, it is indicated that the compound has a low risk of cardiotoxicity. The compound of the present invention can be used alone as a treatment medication for type II diabetes, or be used in combination with a polypeptide GLP-1 receptor agonist such as liraglutide, or be used in combination with the treatment medication for type II diabetes of other mechanisms.
Inventors:
XIE FANG (CN)
YU GUANGXIA (CN)
ZHANG SHUJUAN (CN)
YU GUANGXIA (CN)
ZHANG SHUJUAN (CN)
Application Number:
PCT/CN2020/104059
Publication Date:
February 04, 2021
Filing Date:
July 24, 2020
Export Citation:
Assignee:
THE TITAN LEADING MED TECH INC (CN)
International Classes:
C07D405/14; A61K31/4545; A61K31/4709; A61K31/496; A61K45/06; A61P3/00; A61P3/04; A61P3/10; C07D401/14; C07D413/14; C07D471/04
Domestic Patent References:
| WO2020103815A1 | 2020-05-28 | |||
| WO2019239371A1 | 2019-12-19 | |||
| WO2018192973A1 | 2018-10-25 |
Foreign References:
| TW201835066A | 2018-10-01 |
Other References:
PURANDARE A V; WAN H; GAO A; SOMERVILLE J; BURKE C; VACCARO W; YANG X; MCINTYRE K W; POSS M A: "Optimization of CCR4 Antagonists: Side-Chain Exploration", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 1, 19 October 2005 (2005-10-19), pages 204 - 207, XP027965971, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2005.09.022
Attorney, Agent or Firm:
BEIJING LINKTEC IP LAW FIRM (SPECIAL GENERAL PARTNERSHIP) (CN)
Download PDF: